<p>Sonoma Pharmaceuticals, Inc.（“公司” 或 “Sonoma Pharmaceuticals”）（NASDAQ:SNOA）是一家全球领先的次氯酸（HOCl）技术医疗保健公司，今天宣布其公开发行的定价，该发行以固定承诺的方式进行，预计公司将获得约 400 万美元的总收益，未扣除公司需支付的费用和其他开支。此次发行包括 2,962,963 股普通股和 2,962,963 个认股权证。每股普通股的销售价格为 1.35 美元。认股权证的行使价格为每股 1.35 美元。</p>
<p>此外，Sonoma Pharmaceuticals 已授予 Dawson James Securities 一个为期 45 天的选择权，以购买最多 15% 在此次发行中出售的股份或认股权证，仅用于覆盖超额配售（如有）。</p>
<p>此次发行预计将于 2026 年 4 月 27 日完成，前提是满足惯常的交割条件。</p>
<p>公司预计将把此次发行的净收益用于一般企业用途，包括营运资金。</p>
<p>Dawson James Securities 担任此次发行的唯一账簿管理人。</p>
<p>与此次证券发行相关的 S-1 表格注册声明已向美国证券交易委员会（SEC）提交，并于 2026 年 4 月 23 日获得 SEC 的有效声明。此次发行仅通过招股说明书进行。有关拟议交易条款的最终招股说明书可在 SEC 的网站 www.sec.gov 上获取，或通过联系 Dawson James Securities 获取。本新闻稿不构成出售这些证券的要约或购买这些证券的要约邀请，也不应在任何州或司法管辖区进行证券的销售，除非在任何此类州或司法管辖区的证券法下进行注册或资格审查。</p>
<p><strong>关于 Sonoma Pharmaceuticals</strong></p>
<p>Sonoma Pharmaceuticals 是一家全球医疗保健领导者，专注于开发和生产稳定的次氯酸（HOCl）产品，广泛应用于伤口护理、眼部护理、皮肤病、足病、动物医疗和无毒消毒剂。Sonoma 的产品经过临床验证，能够安全有效地减少瘙痒、疼痛、疤痕和刺激，而不会损害健康组织。对 HOCl 的体外和临床研究表明，它能够安全管理皮肤擦伤、裂伤、轻微刺激、切口和完整皮肤。Sonoma 的产品在全球 55 个国家通过直接销售或合作伙伴销售，公司积极寻求新的分销合作伙伴。公司的主要办公室位于科罗拉多州博尔德，制造业务位于墨西哥瓜达拉哈拉。欧洲市场营销和销售总部位于荷兰罗 ermond。更多信息请访问 www.sonomapharma.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>除本文中的历史信息外，本新闻稿中所述事项属于 1995 年《私人证券诉讼改革法案》“安全港” 条款下的前瞻性声明，包括关于 Sonoma Pharmaceuticals, Inc.及其子公司的商业和技术进展及未来财务表现的声明（“公司”）。这些前瞻性声明通过使用 “继续”、“开发”、“预期”、“期待” 和 “扩展” 等词语来识别。新闻稿中的前瞻性声明受到公司业务固有的某些风险和不确定性的影响，这可能导致实际结果有所不同，包括监管临床和指导方针的发展可能会发生变化，科学数据可能不足以满足监管标准或获得所需的监管许可或批准，临床结果可能无法在实际患者环境中复制，公司专利和专利申请所提供的保护可能会受到竞争对手的挑战、无效或规避，公司产品的可用市场可能没有预期的那么大，公司产品可能无法进入一个或多个目标市场，收入可能不足以满足公司的现金需求，资助进一步开发，满足不同国家和市政当局的多种监管和市场要求的能力，以及公司在向证券交易委员会提交的文件中不时详细说明的其他风险。除法律要求外，公司不承担更新这些前瞻性声明的任何义务。</p>
<p>Sonoma Pharmaceuticals™和 Microcyn®是 Sonoma Pharmaceuticals, Inc.的商标或注册商标。所有其他商标和服务标志均为其各自所有者的财产。</p>
<p><strong>媒体和投资者联系：</strong></p>
<p>Sonoma Pharmaceuticals, Inc.</p>
<p>ir@sonomapharma.com</p>
<p><strong>来源：</strong> Sonoma Pharmaceuticals, Inc.</p>
<p>查看原始新闻稿，请访问 ACCESS Newswire</p>
<p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTE2MDg5NA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTE2MDg5NA"/></p>

Sonoma制药

标普生物技术 ETF - SPDR

生物科技 ETF - VanEck Vectors

<p>Sonoma Pharmaceuticals, Inc.（纳斯达克代码：SNOA）宣布了一项公开发行的定价，预计将筹集约 400 万美元。此次发行包括 2,962,963 股普通股和认股权证，每股定价为 1.35 美元。Dawson James Securities 是唯一的账簿管理人，发行预计将在 2026 年 4 月 27 日完成，具体取决于常规条件。筹集的资金将用于一般企业用途。已向美国证券交易委员会（SEC）提交了注册声明，发行仅通过招股说明书进行</p>

<p>Sonoma Pharmaceuticals, Inc. (the &#34;Company&#34; or &#34;Sonoma Pharmaceuticals&#34;) (NASDAQ:SNOA), a global healthcare leader in hypochlorous acid (HOCl) technology, today announced the pricing of its public offering made on a firm commitment basis with gross proceeds to the Company expected to be approximately $4.0 million, before deducting fees and other expenses payable by the Company. The offering consists of 2,962,963 shares of common stock and 2,962,963 warrants. Each share of common stock is being sold at a purchase price of $1.35 per share. The warrants have an exercise price of $1.35 per share.</p>
<div class="lb-trans"><p>Sonoma Pharmaceuticals, Inc.（“公司” 或 “Sonoma Pharmaceuticals”）（NASDAQ:SNOA）是一家全球领先的次氯酸（HOCl）技术医疗保健公司，今天宣布其公开发行的定价，该发行以固定承诺的方式进行，预计公司将获得约 400 万美元的总收益，未扣除公司需支付的费用和其他开支。此次发行包括 2,962,963 股普通股和 2,962,963 个认股权证。每股普通股的销售价格为 1.35 美元。认股权证的行使价格为每股 1.35 美元。</p>
</div><p>In addition, Sonoma Pharmaceuticals has granted Dawson James Securities a 45-day option to purchase up to 15% of the number of shares or warrants sold in the offering solely to cover over-allotments, if any.</p>
<div class="lb-trans"><p>此外，Sonoma Pharmaceuticals 已授予 Dawson James Securities 一个为期 45 天的选择权，以购买最多 15% 在此次发行中出售的股份或认股权证，仅用于覆盖超额配售（如有）。</p>
</div><p>The offering is expected to close on April 27, 2026, subject to the satisfaction of customary closing conditions.</p>
<div class="lb-trans"><p>此次发行预计将于 2026 年 4 月 27 日完成，前提是满足惯常的交割条件。</p>
</div><p>The Company expects to use the net proceeds from the offering for general corporate purposes, including working capital.</p>
<div class="lb-trans"><p>公司预计将把此次发行的净收益用于一般企业用途，包括营运资金。</p>
</div><p>Dawson James Securities is acting as sole bookrunner for the offering.</p>
<div class="lb-trans"><p>Dawson James Securities 担任此次发行的唯一账簿管理人。</p>
</div><p>A registration statement on Form S-1 relating to the offering of the securities was filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on April 23, 2026. The offering is being made only by means of a prospectus. A final prospectus describing the terms of the proposed transaction may be obtained, when available, on the SEC's website, www.sec.gov or by contacting Dawson James Securities. This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>与此次证券发行相关的 S-1 表格注册声明已向美国证券交易委员会（SEC）提交，并于 2026 年 4 月 23 日获得 SEC 的有效声明。此次发行仅通过招股说明书进行。有关拟议交易条款的最终招股说明书可在 SEC 的网站 www.sec.gov 上获取，或通过联系 Dawson James Securities 获取。本新闻稿不构成出售这些证券的要约或购买这些证券的要约邀请，也不应在任何州或司法管辖区进行证券的销售，除非在任何此类州或司法管辖区的证券法下进行注册或资格审查。</p>
</div><p><strong>About Sonoma Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>关于 Sonoma Pharmaceuticals</strong></p>
</div><p>Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com.</p>
<div class="lb-trans"><p>Sonoma Pharmaceuticals 是一家全球医疗保健领导者，专注于开发和生产稳定的次氯酸（HOCl）产品，广泛应用于伤口护理、眼部护理、皮肤病、足病、动物医疗和无毒消毒剂。Sonoma 的产品经过临床验证，能够安全有效地减少瘙痒、疼痛、疤痕和刺激，而不会损害健康组织。对 HOCl 的体外和临床研究表明，它能够安全管理皮肤擦伤、裂伤、轻微刺激、切口和完整皮肤。Sonoma 的产品在全球 55 个国家通过直接销售或合作伙伴销售，公司积极寻求新的分销合作伙伴。公司的主要办公室位于科罗拉多州博尔德，制造业务位于墨西哥瓜达拉哈拉。欧洲市场营销和销售总部位于荷兰罗 ermond。更多信息请访问 www.sonomapharma.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the &#34;safe harbor&#34; provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the &#34;company&#34;). These forward-looking statements are identified by the use of words such as &#34;continue,&#34; &#34;develop,&#34; &#34;anticipate,&#34; &#34;expect&#34; and &#34;expand,&#34; among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs, fund further development, the ability to meet a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.</p>
<div class="lb-trans"><p>除本文中的历史信息外，本新闻稿中所述事项属于 1995 年《私人证券诉讼改革法案》“安全港” 条款下的前瞻性声明，包括关于 Sonoma Pharmaceuticals, Inc.及其子公司的商业和技术进展及未来财务表现的声明（“公司”）。这些前瞻性声明通过使用 “继续”、“开发”、“预期”、“期待” 和 “扩展” 等词语来识别。新闻稿中的前瞻性声明受到公司业务固有的某些风险和不确定性的影响，这可能导致实际结果有所不同，包括监管临床和指导方针的发展可能会发生变化，科学数据可能不足以满足监管标准或获得所需的监管许可或批准，临床结果可能无法在实际患者环境中复制，公司专利和专利申请所提供的保护可能会受到竞争对手的挑战、无效或规避，公司产品的可用市场可能没有预期的那么大，公司产品可能无法进入一个或多个目标市场，收入可能不足以满足公司的现金需求，资助进一步开发，满足不同国家和市政当局的多种监管和市场要求的能力，以及公司在向证券交易委员会提交的文件中不时详细说明的其他风险。除法律要求外，公司不承担更新这些前瞻性声明的任何义务。</p>
</div><p>Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.</p>
<div class="lb-trans"><p>Sonoma Pharmaceuticals™和 Microcyn®是 Sonoma Pharmaceuticals, Inc.的商标或注册商标。所有其他商标和服务标志均为其各自所有者的财产。</p>
</div><p><strong>Media and Investor Contact:</strong></p>
<div class="lb-trans"><p><strong>媒体和投资者联系：</strong></p>
</div><p>Sonoma Pharmaceuticals, Inc.</p>
<div class="lb-trans"><p>Sonoma Pharmaceuticals, Inc.</p>
</div><p>ir@sonomapharma.com</p>
<div class="lb-trans"><p>ir@sonomapharma.com</p>
</div><p><strong>SOURCE:</strong> Sonoma Pharmaceuticals, Inc.</p>
<div class="lb-trans"><p><strong>来源：</strong> Sonoma Pharmaceuticals, Inc.</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看原始新闻稿，请访问 ACCESS Newswire</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTE2MDg5NA" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1160894"/></p>

Sonoma 制药宣布 400 万美元公开发行的定价 | SNOA 股票新闻